ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020

  • Post author:
  • Post category:Newsroom

Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update.

  • TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer
  • NOPHO-sponsored Phase 2 trial in acute lymphoblastic leukemia
  • Appointment of Dr. Stewart Craig as Chief Technical Officer
  • Cash and cash equivalents of €40.5 million ($47.5 million) at the end of September 2020
  • €10 million ($11.7 million) in non-dilutive financing secured in the form of state-guaranteed loans